BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • COVID-19 : Serum, Bharat Biotech...
      Coronavirus

      COVID-19 : Serum, Bharat Biotech Vaccines Approved For Emergency Use

      Subject Expert Committee of the Central Drugs Standards Control Organization met on January 1 and 2 to discuss the two vaccines.

      By - Shachi Sutaria |
      Published -  2 Jan 2021 9:28 PM IST
    • Boomlive
      COVID-19 : Serum, Bharat Biotech Vaccines Approved For Emergency Use

      Covishield and Covaxin, vaccines against Coronavius, have been given the go ahead for emergency use authorisation the Drugs Controller General of India, who is yet to announce when the vaccine will be rolled out in the country.

      The recommendation for Covaxin and Covishield came from the Subject Expert Committee (SEC) of India's Central Drugs Standards Control Organisation (CDSCO). The panel permitted restricted emergency usage of both the vaccines, subject to unspecified multiple regulatory conditions.

      #COVID19Update

      Subject Expert Committee (SEC) of @CDSCO_INDIA_INF makes recommendations in respect of accelerated Approval Process request of @SerumInstIndia, @BharatBiotech & Phase-III Trials of M/s Cadila Healthcare Ltd.https://t.co/hwNyTYqSJM pic.twitter.com/9uLOrjV7cQ

      — Ministry of Health (@MoHFW_INDIA) January 2, 2021

      Serum Institute of India is manufacturing Covishield, the adenoviral vector vaccine that is produced by Oxford-AstraZeneca. This vaccine which was undergoing Phase III trials in India received emergency approval in the United Kingdom on December 31. A reported effectiveness between 62-90 percent, this vaccine transfers the spike protein of SARS-CoV-2 and helps the body elicit an immune response.

      Also Read:UK Approves Oxford-AstraZeneca COVID-19 Vaccine, Roll Out From Jan 4

      Covaxin, India's indigenous vaccine candidate is prepared by Bharat Biotech with a strain isolated by the country's National Institute of Virology and uses the inactivated virus with adjuvants, to create antibodies against the virus. Still in the clinical trial phase, Covaxin, received the panel's nod in "public interest as an abundant precaution" with the statement adding, "in clinical trial mode, (e)specially in the context of infection by mutant strains". The Ministry and Bharat Biotech are yet to clarify the specifics of the caveats in Covaxin's approval. From the 25,800 people who participated in the trials, over 22,000 have received either the vaccine or a placebo. The efficacy data of this vaccine is still awaited.

      The DCGI has also accepted the panel's recommendation to grant approval to Cadila Healthcare to conduct the third phase trials for its vaccine - ZyCov-D.

      After a vaccine dry run in four states - Assam, Andhra Pradesh, Punjab and Gujarat, the Centre conducted a dry run for the vaccine in all states and union territories. The roll out checked the distribution methods, registration, administering of the vaccine.

      Also Read:Centre To Use Electoral Roll To Identify Who Receives COVID-19 Vaccine

      India reported 18,177 cases in 24 hours, taking the total number 1,03,23,965 cases on Saturday. We also reported 217 deaths in a single day, with the death toll currently at 1,49,435. Of the reported 2,47,220 active cases, 29 cases are those positive for the new mutated coronavirus.

      (Editor's Note: This story has been updated with after the DCGI's press conference)


      Tags

      COVID-19serum institute of indiabharat biotechcovishield
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!